Stay updated on Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial
Sign up to get notified when there's something new on the Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial page.

Latest updates to the Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision: v3.4.2 is now displayed and the prior revision (v3.4.1) was removed. This change does not affect study details, eligibility criteria, or outcomes on the page.SummaryDifference0.4%

- Check15 days agoChange DetectedA site-wide notice about a lapse in government funding is now displayed, and the page revision has been updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check22 days agoChange DetectedAdditions include showing the glossary and new status fields such as Results First Posted, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0; deletions remove Results First Posted (Estimated), Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check36 days agoChange DetectedResults updates were added, including Clinical Benefit Rate (CBR) in PD-1 naive patients, overall survival (OS), progression-free survival (PFS), and brain-specific safety data, with the corresponding submission dates. Study documents such as the Protocol and Statistical Analysis Plan PDF were also added to the page.SummaryDifference3%

- Check57 days agoChange DetectedAdded a Locations section displaying Texas as a study location and removed the Texas Locations and HHS Vulnerability Disclosure links.SummaryDifference0.2%

- Check86 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2, with no changes to study content or core functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Low Dose Ipilimumab With Pembrolizumab in Brain Metastases Clinical Trial page.